IR Information
IR Information
News Release
News release
-
2026.03.12
Notice of Initiation of Phase III Clinical Trial (Physician-Initiated Trial) for LT-5001 in Trigeminal Neuralgia
(254KB)
-
2026.03.10
Request for notification of changes to shareholder register entries, such as address changes
(251KB)
-
2026.03.09
Announcement of Completion of Investigational Drug Administration in the Phase IIa Clinical Trial of PC-SOD
(264KB)
-
2026.01.23
Notice of Presentation at ASCO-GI 2026 Regarding Our Phase III Clinical Trial
(419KB)
-
2025.12.15
Announcement of Presentation at the 12th Neko no Syukai
(187KB)
Financial Information
Disclosure
Financial Results
| 23rd Fiscal Period (Results for March 2025) | |
|---|---|
| Net sales (Thousands of yen) | 61,438 |
| Operating income (thousand yen) | 1,420,545 |
| Net income (thousand yen) | 1,084,701 |
| Net assets (Thousands of yen) | 5,257,192 |
| Total assets (Thousands of yen) | 5,585,185 |
| Equity ratio (%) | 94.1 |
Business Report
Business report
23rd Term
Business Overview
(544KB)
22nd Term
Business Overview
(558KB)
21th Term
Business Overview
(485KB)
20th Term
Business Overview
(568KB)
19th Term
Business Overview
(595KB)
